Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.